Thor Equities Group inks Jersey City lease with cutting-edge maker of edible proteins

Fork & Goode to occupy 11,855 sq. ft. of 3rd-floor lab sciences space, joining RWJBarnabas Health/JCMC

Real estate developer Thor Equities Group helped secure a long-term lease with Fork & Goode for 11,855 square feet at 95 Greene St. in Jersey City.

Fork & Goode is pioneering a new approach to growing meat. The Brooklyn, New York-based company said its goal is “to create delicious and healthy meat products to help meet our growing protein needs.” Cultivated Meat is produced using cell culture technology to grow meat cells that have flavor and key nutrients.

“We are very pleased to welcome Fork & Goode to 95 Greene St. The space offers state-of-the-art infrastructure to deliver an environment the inventive company will thrive in,” said Jack Sitt, executive vice President of Thor Equities Group.

Encompassing 350,000 square feet over eight levels, 95 Greene St. previously served as a manufacturing facility for Colgate Palmolive until 1987 and was later converted into a Class -A office building occupied by Merrill Lynch.

The property offers an incredible amount of power resources served by multiple utility grids, 13- to 15-foot ceiling heights, secured interior loading docks, on-site life-safety generator and flexible floor plates. Onsite underground parking is available for 125 vehicles.

Thor worked with SGA Architects to complete a comprehensive adaptive reuse project for 95 Greene St. Base building work included extensive upgrades to mechanicals, HVAC, vertical conduits and a new rooftop generator.

Thor’s life science portfolio includes two additional life science facilities in New Jersey; 7 Powder Horn Drive in Warren, which is occupied by Celgene BMS; and the New Jersey Center of Excellence in Bridgewater, a 784,000-square-foot secure campus leased to life science companies including anchor tenants Nestlé Health Science, Ashland, Amneal Pharmaceuticals and PTC Therapeutics.

The JLL team of Dan Loughlin, vice chairman; Dan Spero, senior managing director; Bob Ryan and Craig Eisenhardt, managing directors; Blake Goodman, executive vice president; and John Cahill, senior vice president, represented Thor Equities in the transaction.